For investors
Technical scrutiny across the full deal cycle.
Private equity firms, financial investors and family offices with holdings in pharma, biotech, MedTech and IVD: from regulatory due diligence before signing through value creation during the hold period to sale readiness ahead of the exit.
Value creation
Operational value creation during the hold period: manufacturing excellence, quality system remediation, supply chain and digitalisation.
Our expertise
The same scrutiny, across all five areas of expertise.
A deal rarely touches just one discipline. We assess a target or portfolio company with the same specialist teams that run approvals, pass audits and relocate production day to day. What changes is only the question put first: the investor’s.
For investors
How we deliver.
For the phases after closing we do not act as assessors but as implementers: 100-day plan, transformation PMO, KPI tracking and workstream steering, with interim staffing where needed. Governance sits with a steering committee of investor and management, the PMO coordinates and reports, the operational workstreams execute.
Experience on both sides.
We work for manufacturers and for investors. That is not a contradiction but the reason the assessment holds: whoever has lived through audits, submissions and inspections recognises faster which finding touches the deal and which is merely a footnote. Before any buy-side mandate we check for conflicts of interest with existing client relationships.